FDA Grants Appili Orphan Drug Status

After growing quietly for several months, Appili Therapeutics Inc. of Halifax announced Tuesday it has received a key U.S. regulatory designation for a drug that treats Clostridium difficile infection, or CDI, in children.
The company said in a statement the Food and Drug Administration has granted orphan drug designation to its drug candidate ATI-1501. This medicine removes the bitter taste